Shaheen Khan

Employment

• University of Texas Southwestern Medical Center

Education

• Texas A&M University Ph.D.

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• T-cell tolerant fraction as a predictor of immune-related adverse events.
  Journal for immunotherapy of cancer 2023 DOI: 10.1136/jitc-2022-006437
  +Save
• Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.
  Cancers 2022 DOI: 10.3390/cancers14051327
  +Save
• Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
  Journal for immunotherapy of cancer 2021 DOI: 10.1136/jitc-2021-002349
  +Save
• Melanoma models for the next generation of therapies.
  Cancer cell 2021 DOI: 10.1016/j.ccell.2021.01.011
  +Save
• Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.
  Clinical chemistry 2020 DOI: 10.1093/clinchem/hvaa081
  +Save
• Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
  The oncologist 2020 DOI: 10.1634/theoncologist.2019-0911
  +Save
• Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon.
  The oncologist 2020 DOI: 10.1634/theoncologist.2019-0666
  +Save
• MIR205HG Is a Long Noncoding RNA that Regulates Growth Hormone and Prolactin Production in the Anterior Pituitary.
  Developmental cell 2019 DOI: 10.1016/j.devcel.2019.03.012
  +Save
• Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells with ddSEQ.
  Methods in molecular biology (Clifton, N.J.) 2019 DOI: 10.1007/978-1-4939-9240-9_10
  +Save
• Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
  Seminars in cancer biology 2019 DOI: 10.1016/j.semcancer.2019.06.012
  +Save